What is ADAMTS13 Activity?
ADAMTS13 activity refers to the functional capacity of the ADAMTS13 metalloprotease enzyme to cleave ultra-large von Willebrand factor (UL-VWF) multimers in the bloodstream, with normal activity levels around 100% (or 100 IU/dL) and severe deficiency defined as <10% activity. 1
Biological Function and Mechanism
ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs, member 13) is a zinc-containing metalloprotease produced primarily by hepatic stellate cells and likely endothelial cells. 1 Once released into circulation, it performs a critical regulatory function:
- Cleaves a single peptide bond (Tyr1605-Met1606) in the central A2 domain of VWF molecules 2
- Reduces the size of ultra-large VWF multimers that would otherwise accumulate on endothelial surfaces and in circulating blood 1
- Prevents excessive platelet adhesion and aggregation that leads to microvascular thrombosis 1
- Regulates hemostasis and inflammatory responses through this proteolytic activity 1
Clinical Significance of ADAMTS13 Activity Levels
Severe Deficiency (<10% activity)
When plasma ADAMTS13 activity falls below 10 IU/dL (or 10% of normal), the diagnosis of thrombotic thrombocytopenic purpura (TTP) should be considered in the proper clinical context. 1 This threshold has:
- 97% sensitivity and 100% specificity for TTP diagnosis 3
- Leads to accumulation of UL-VWF multimers
- Triggers microvascular thrombus formation throughout the body
- Results in ischemic organ damage and potential mortality 1
Moderate Deficiency
Moderate ADAMTS13 deficiency may occur in:
- Complement-mediated hemolytic uremic syndrome (HUS)
- Sepsis
- Autoimmune conditions 3
These conditions can have prothrombotic and proinflammatory consequences even without reaching the severe deficiency threshold. 4
Causes of ADAMTS13 Deficiency
Immune-mediated (iTTP)
- Autoantibodies against ADAMTS13 1
- Most common form of TTP
- Detectable anti-ADAMTS13 IgG antibodies (though may be absent initially) 1
Congenital (cTTP)
- Mutations in the ADAMTS13 gene (approximately 250 causative mutations identified) 1
- Autosomal recessive inheritance
- Results in either impaired secretion or non-functional protease 1
Laboratory Testing Considerations
The sample for ADAMTS13 activity testing must be drawn before the first therapeutic plasma exchange (TPE) session. 3 If this is not possible, a sample obtained the next day just before the next TPE session remains useful. 3
Important Testing Caveats:
- No single test is fully reliable - if ADAMTS13 activity >10% is found in a patient with suggestive clinical picture, further assays using different techniques should be performed 3
- Falsely low results are the most frequent challenge with automated or semi-quantitative assays 3
- When results seem discordant with clinical presentation, a FRET assay should be obtained 3
- Various assay platforms exist including flow cytometric methods, ELISA-based assays, and other functional assays 5, 6
Beyond TTP: Broader Clinical Relevance
ADAMTS13 activity has implications beyond TTP diagnosis:
- Thrombotic microangiopathies (TMAs) in general 4
- Ischemic stroke and coronary artery disease risk assessment 4
- COVID-19 and severe infections (relative ADAMTS13 deficiency may contribute to thrombosis risk) 6
- Cancer and other prothrombotic states 6
The measurement of ADAMTS13 activity has evolved from labor-intensive methods to rapid, automated platforms, improving clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. 7